Adrenal GRK2 inhibition could be also positive and valuable as a therapy for other diseases characterized by sympathetic hyperactivity as hypertension (Schlaich et al., 2004), hyperthyroidism (Foley et al., 2001), pheochromocytoma (Roghi et al., 2011) or some cognitive, and psychiatric disorders as depression (Hausberg et al., 2007; Femminella et al., 2013b). This evidence concerns the gene GRK2 and depressive disorder.